In addition, investigating the loci with clear candidate genes and association with multiple inflammatory diseases showing a consistent direction of effects, such as 11p13 (PRR5L—multiple sclerosis, asthma), 11q24 (ETS1—psoriasis, celiac disease), and 16p13.13 (DEXI and CLEC16A—type-I diabetes, multiple sclerosis, alopecia areata, systemic lupus erythematosus, asthma), may reveal promising targets with potential drug repurposing future. This evidence concerns the gene ETS1 and asthma.